|
| Press Releases |
|
 |
|
| Thursday, June 22, 2023 |
|
|
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NOH"), Eisai's digital tool for self-assessment of cognitive function, will continue to be promoted as part of the FY2023 dementia examination project, conducted by Bunkyo City, Tokyo. more info >> |
|
|
エーザイ、東京都文京区の2023年度認知症検診事業において「のうKNOW(R)」による脳の健康度測定を継続実施 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、東京都文京区(以下、文京区)が実施する2023年度認知症検診事業（以下、本事業）において、当社の認知機能のデジタルチェックツール「のうKNOW(R)」による脳の健康度測定が継続実施されることをお知らせします。 more info >> |
|
| Monday, June 12, 2023 |
|
|
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai's Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use for the treatment of Alzheimer's disease (AD). more info >> |
|
|
エーザイ、米国FDA諮問委員会は全会一致でアルツハイマー病治療薬「LEQEMBI(R)」（レカネマブ）の臨床上のベネフィットを支持 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、米国食品医薬品局（FDA）の末梢・中枢神経系薬物諮問委員会（Peripheral and Central Nervous System Drugs Advisory Committee、以下 本諮問委員会）が開催され、「LEQEMBI(R)」注射100 mg/mL溶液（一般名：レカネマブ）の臨床第III相Clarity AD検証試験の結果が、本剤の臨床上のベネフィットを示すエビデンスであることが、全会一致で支持されましたのでお知らせします。 more info >> |
|
| Thursday, June 8, 2023 |
|
|
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea |
| This application is the first application for lecanemab in Asia outside of Japan and China. Eisai plans to submit additional applications in other Asian countries. more info >> |
|
|
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、韓国において早期アルツハイマー病に係る適応で新薬承認を申請 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、エーザイが抗アミロイドβ（Aβ）プロト フィブリル*抗体レカネマブ（一般名、米国ブランド名：「LEQEMBI(R)」）について、脳内アミロイド病理が確認された早期アルツハイマー病（アルツハイマー病（AD）による軽度認知障害および軽度認知症）に係る適応で、韓国食品医薬品安全処（MFDS）に新薬承認申請を行いましたのでお知らせします。 more info >> |
|
| Friday, June 2, 2023 |
|
|
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting |
| Eisai Co., Ltd. announced a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO), will be given at the 37th annual meeting of the Associated Professional Sleep Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States. more info >> |
|
| Friday, May 26, 2023 |
|
|
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma |
| These data will be presented on Monday, June 5 at 11:54 a.m. Central Daylight Time during an oral abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #4502). more info >> |
|
| Thursday, May 25, 2023 |
|
|
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria |
| Eisai Co., Ltd. has announced that it will grant a total of 625 million yen to the Global Health Innovative Technology Fund ("GHIT Fund") to fund the third phase of its activities, which will take place in the five-year period from FY2023 to FY2027. more info >> |
|
| Wednesday, May 24, 2023 |
|
|
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO23), which is taking place virtually and in-person in Chicago, Illinois from June 2 to 6. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Sharp to Exhibit at The 3rd SPEXA - Space Business Expo
May 18, 2026 17:34 JST
|
|
|
Your Go-To Travel Checklist for Smarter, Reward-Focused Travel Planning
May 18, 2026 16:32 HKT/SGT
|
|
|
Tabor Redefines Anti-Drone Testing with Software-Defined SDR Platform
May 18, 2026 16:30 HKT/SGT
|
|
|
MHIEC Receives Waste Treatment Technology Verification Report from JESC for Its Fluidized Bed-type Gasification and Reforming System
May 18, 2026 17:17 JST
|
|
|
2026年、日本の音楽サブスク利用意識に変化——料金・通信環境・音質から見る新たな比較基準
May 18, 2026 16:00: JST
|
|
|
MHI Thermal Systems Receives A' Design Awards
-- Recognition at Italy's International Design Competition for the Hydrolution EZY Series of Air-to-Water Heat Pumps and the ZT Series of Residential-Use Air-Conditioners --
May 18, 2026 16:26 JST
|
|
|
エーザイ、「SX 銘柄 2026」に初選定
May 18, 2026 14:50: JST
|
|
|
MHIEC、「流動床式ガス化改質システム」の廃棄物処理技術検証結果書を日本環境衛生センターから取得
May 18, 2026 14:50: JST
|
|
|
Tallgrass and Mitsubishi Power Americas Announce Turbine Allocation for Cheyenne Power Hub
May 18, 2026 15:15 JST
|
|
|
Paying Off Debt but Still Want to Save? Here's How to Manage Both
May 18, 2026 14:00 HKT/SGT
|
|
|
S CUBE Capital Announces Strategic Acquisition by InCred Capital to enhance Global Asset Management Capabilities
May 18, 2026 12:30 HKT/SGT
|
|
|
三菱重工、長崎海運人材育成協会向けCTVのウォータージェット推進装置を受注
May 18, 2026 12:20: JST
|
|
|
三菱重工サーマルシステムズ、伊「A'デザインアワード2026」を受賞
May 18, 2026 12:15: JST
|
|
|
JCB and Wonder Advance Cashless Taxi Payments in Hong Kong
May 18, 2026 10:00 JST
|
|
|
「星樞計劃」正式發布 鈞達股份多家下屬公司成為上海太空算力產業生態夥伴發起及首批單位
May 17, 2026 12:51 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
